UK Markets open in 7 hrs 20 mins
  • NIKKEI 225

    29,639.40
    -200.31 (-0.67%)
     
  • HANG SENG

    24,221.54
    +122.40 (+0.51%)
     
  • GOLD FUTURES

    1,768.40
    -9.80 (-0.55%)
     
  • DOW

    34,258.32
    +338.48 (+1.00%)
     
  • BTC-GBP

    31,536.87
    +87.86 (+0.28%)
     
  • CMC Crypto 200

    1,089.55
    +49.07 (+4.72%)
     
  • Nasdaq

    14,896.85
    +150.45 (+1.02%)
     
  • ^FTAS

    4,081.81
    +52.80 (+1.31%)
     

Can CureVac Win Market Share With Only 48% Vaccine Efficacy?

·4-min read
Can CureVac Win Market Share With Only 48% Vaccine Efficacy?
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

CureVac (NASDAQ: CVAC) surprised investors a few weeks ago when it announced disappointing data from a trial of its mRNA vaccine candidate. Many expected the German biotech would follow in the footsteps of fellow mRNA vaccine makers Pfizer and Moderna. After the CureVac report, it looked like company's dreams of a spot in the vaccine market were over -- at least in the near term.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting